Navigation Links
OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
Date:5/30/2009

with OGX-011 in metastatic castrate resistant prostate cancer, subject to the receipt of additional funding. The U.S. Food & Drug Administration (FDA) has agreed on the design of two Phase 3 registration trials, via the Special Protocol Assessment (SPA) process, of OGX-011 in combination with second-line chemotherapy. One trial design investigates overall survival as the primary endpoint; the other trial design investigates pain palliation as the primary endpoint. Based on the survival benefit observed after combining OGX-011 with first-line docetaxel chemotherapy, OncoGenex has initiated discussions with the FDA regarding evaluating the overall survival benefit in patients treated with first-line chemotherapy, rather than second-line chemotherapy.

OGX-011 has received Fast Track designation from the FDA for the treatment of progressive metastatic prostate cancer in combination with docetaxel.

About OncoGenex

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address unmet needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the lead candidate currently completing five Phase 2 clinical trials in prostate, lung and breast cancers, is designed to inhibit the production of a specific protein associated with treatment resistance; OGX-427 is in Phase 1 clinical development; SN2310 has completed the Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development.

OGX-011, OGX-427 and OGX-225 utilize second-generation antisense technology, licensed from Isis Pharmaceuticals (NASDAQ: ISIS), to effectively target and inhibit production of specific proteins in tumor cells. OncoGen
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
2. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
3. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
4. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
5. OncoGenex Reports First Quarter Financial Results
6. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
7. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
8. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
9. OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
10. OncoGenex Pharmaceuticals to Webcast Financial Results for Fourth Quarter and Fiscal Year 2008 and Provide Outlook for 2009
11. OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... DTS Language Services, Inc . is pleased ... Life Science organizations who need document translations. Clients will ... their documents in advance with a selection of nearly 50 ... often a critical factor in clinical and scientific fields, and ...
(Date:1/15/2014)... 15, 2014 AudioNotch is the internet's ... for the treatment of tinnitus. Patients listen to sound ... over a period of weeks to months, their tinnitus volume ... two forms: Notched Music and Notched White Noise. Now, AudioNotch ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Carahsoft and ... Thursday, January 23, 2014 at 2pm EST (11am PST), ... The topic focuses on how technology can turn raw, ... decisions for government agencies. The online webinar will last ...
(Date:1/14/2014)... , Jan. 14, 2014 As pet owners drew up ... many of them wrote: "Take better care of my furry companion." ... designer clothes and top-brand carrying cases to take the little canine ... might also feel compelled to buy some pricey toys at the ...
Breaking Biology Technology:DTS Improves Efficiency for Life Science Document Translations 2Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2
... loss is a major cause of death from roadside bombs ... for people age 4 to 44, often overwhelms the body,s ... natural process, a team led by Erin Lavik, a new ... doctoral student, James P. Bertram, built synthetic platelets that show ...
... Care at Hahnemann among the Best in the Nation ... it has been granted Magnet(R) recognition by the American Nurses ... the highest levels of recognition a hospital or medical center ... hospitals in the country that have achieved this prestigious distinction. ...
... , , , , WALTHAM, ... world,s leading research and advisory firms for pharmaceutical and ... dermatologists, Centocor Ortho Biotech/Janssen-Cilag,s Stelara and Abbott,s briakinumab (both ... share in 2012 in the drug market for moderate ...
Cached Biology Technology:Researchers take the inside route to halt bleeding 2Hahnemann University Hospital Granted Magnet(R) Status 2Hahnemann University Hospital Granted Magnet(R) Status 3In 2012, Stelara and Briakinumab Will Capture 22 Percent of the Biologics Share in the Moderate to Severe Psoriasis Drug Market 2In 2012, Stelara and Briakinumab Will Capture 22 Percent of the Biologics Share in the Moderate to Severe Psoriasis Drug Market 3
(Date:4/23/2014)... contribute to early fetal death according to a new ... Children,s Hospital Los Angeles and Ulaanbaatar, Mongolia the ... paper published today in the journal BMC Pregnancy ... between seasonal ambient air pollutants and pregnancy loss in ... the highest levels of air pollution of all world ...
(Date:4/23/2014)... Like a hungry diner ripping open a dinner roll, ... must tear open a hydrogen molecule. Now researchers have ... the two halves of its hydrogen feast. The view ... make the catalyst work better for alternative energy uses. ... shown precisely where the hydrogen halves end up in ...
(Date:4/23/2014)... research shows that male black widow spiders prefer their ... example of mate preference by male spiders. ... and Maydianne Andrade, a professor in UTSC,s Department of ... the wild that males overwhelmingly chose to mate with ... can tell whether a potential mate is well-fed and ...
Breaking Biology News(10 mins):Pollutants from coal-burning stoves strongly associated with miscarriages in Mongolia 2Halving hydrogen 2Halving hydrogen 3Halving hydrogen 4Picky male black widow spiders prefer well-fed virgins 2
... Nadeau, PhD, of Case Western Reserve University School of ... (NIH) Director,s Pioneer Award. One of 17 ... investigate transgenerational genetic effects, where the biological features and ... depend as much on the genetics of ancestral generations ...
... A 15-year experiment in an outdoor "laboratory" on Ohio ... just as many, if not more, ecological services as will ... been comparing the behavior of two experimental marshes on the ... and another that was left to colonize plant and animal ...
... in Spanish . A beneficial yeast that ... the fungal culprit behind Fusarium head blight ("scab"). U.S. ... isolated an improved variant of the yeast Cryptococcus flavescens ... as a biocontrol agent. In susceptible wheat and ...
Cached Biology News:Case Western Reserve geneticist receives prestigious NIH Director's Pioneer Award 2Planted, unplanted man-made wetlands are similar at year 15, and function as effective carbon sinks 2Planted, unplanted man-made wetlands are similar at year 15, and function as effective carbon sinks 3Planted, unplanted man-made wetlands are similar at year 15, and function as effective carbon sinks 4Flower-dwelling yeast licensed for use against scab disease 2